ibuprofen has been researched along with Necrotizing Enterocolitis in 21 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
| Excerpt | Relevance | Reference |
|---|---|---|
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| " Moderate certainty evidence showed a reduction in NEC following administration of a combination of species of probiotics, probiotics (any), antenatal corticosteroids in pregnant women at risk of preterm birth, and ibuprofen versus indomethacin for treatment of patent ductus arteriosus (PDA)." | 5.05 | An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants. ( Ei-Saie, A; Maheshwari, A; Neu, J; Pammi, M; Xiong, T, 2020) |
| "A high dose of oral ibuprofen was associated with a higher likelihood of hemodynamically significant PDA closure vs standard doses of intravenous ibuprofen or intravenous indomethacin; placebo or no treatment did not significantly change the likelihood of mortality, necrotizing enterocolitis, or intraventricular hemorrhage." | 4.98 | Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. ( Florez, ID; Mbuagbaw, L; Mitra, S; Sadeghirad, B; Tamayo, ME; Thabane, L; Vanniyasingam, T; Veroniki, AA; Zea, AM; Zhang, Y, 2018) |
| " Oral ibuprofen is associated with lower instance of necrotizing enterocolitis." | 4.95 | Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options. ( Keim-Malpass, J; Prescott, S, 2017) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| "In infants with VLBW, oral ibuprofen is as effective as intravenous indomethacin for closure of PDA and is associated with significantly fewer cases of necrotizing enterocolitis among infants with birth body weights <1250 g and significantly lower rates of elevated creatinine levels among neonates with birth body weights ranging from 1000 to 1500 g." | 3.78 | Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants. ( Chen, HN; Hsiao, CC; Lee, CH; Lee, ML; Tsao, LY, 2012) |
| "Ibuprofen (IBU) has proved as effective as indomethacin in the pharmacological closure of hemodynamically significant patent ductus arteriosus (HsPDA), with an efficacy inversely related to gestational age (57-89%)." | 2.79 | Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants. ( Chiandetti, L; Frigo, AC; Lago, P; Opocher, F; Ricato, S; Salvadori, S, 2014) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.66 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2020) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.61 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2019) |
| "Management of persistently patent ductus arteriosus (PDA) in extremely low-birth-weight infants (ELBWIs) requires attention due to the risk of tissue hypoperfusion." | 1.91 | Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience. ( Ibara, S; Ieiri, S; Ikee, T; Ikoma, S; Kawano, M; Kawano, T; Machigashira, S; Masuya, R; Matsukubo, M; Murakami, M; Muto, M; Nakame, K; Noguchi, H; Sugita, K; Torikai, M, 2023) |
| "Ibuprofen treatment increases the risk for death in preterm infants with NEC." | 1.51 | [Clinical features and outcomes of neonatal necrotizing enterocolitis]. ( Gan, X; Li, J; Mao, J, 2019) |
| "Although the frequency of secondary patent ductus arteriosus (PDA) ligation and the incidence of bronchopulmonary dysplasia (BPD) was higher in the clinical symptoms group in the univariate analysis, after multivariate logistic regression analysis adjusting for the CRIB-II score, birthweight, birth year, and the invasive ventilator care ≤ 2 postnatal days, there were no significant differences in mortality, frequency of secondary ligation and in-hospital outcomes including necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), BPD or death." | 1.46 | Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment. ( Choi, CW; Jung, YH; Kim, BI; Kim, EK; Kim, HS; Lee, JA; Oh, S; Shin, SH; Sohn, JA; Yoo, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hundscheid, T | 3 |
| Onland, W | 3 |
| Kooi, EMW | 3 |
| Vijlbrief, DC | 4 |
| de Vries, WB | 2 |
| Dijkman, KP | 3 |
| van Kaam, AH | 3 |
| Villamor, E | 3 |
| Kroon, AA | 3 |
| Visser, R | 3 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 3 |
| Zecic, A | 3 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Donders, R | 3 |
| Nuytemans, DHGM | 2 |
| Van Overmeire, B | 3 |
| Mulder, AL | 2 |
| de Boode, WP | 4 |
| Muto, M | 1 |
| Sugita, K | 1 |
| Murakami, M | 1 |
| Ikoma, S | 1 |
| Kawano, M | 1 |
| Masuya, R | 1 |
| Matsukubo, M | 1 |
| Kawano, T | 1 |
| Machigashira, S | 1 |
| Nakame, K | 1 |
| Torikai, M | 1 |
| Ikee, T | 1 |
| Noguchi, H | 1 |
| Ibara, S | 1 |
| Ieiri, S | 1 |
| Gan, X | 1 |
| Mao, J | 1 |
| Li, J | 1 |
| Xiong, T | 1 |
| Maheshwari, A | 1 |
| Neu, J | 1 |
| Ei-Saie, A | 1 |
| Pammi, M | 1 |
| Ohlsson, A | 4 |
| Shah, SS | 4 |
| Isayama, T | 1 |
| Kusuda, S | 1 |
| Reichman, B | 1 |
| Lee, SK | 1 |
| Lehtonen, L | 1 |
| Norman, M | 1 |
| Adams, M | 1 |
| Bassler, D | 1 |
| Helenius, K | 1 |
| Hakansson, S | 1 |
| Yang, J | 1 |
| Jain, A | 1 |
| Shah, PS | 1 |
| El Manouni El Hassani, S | 1 |
| Niemarkt, HJ | 1 |
| Derikx, JPM | 1 |
| Berkhout, DJC | 1 |
| Ballón, AE | 1 |
| de Graaf, M | 1 |
| Cossey, V | 1 |
| Hulzebos, CV | 1 |
| Kramer, BW | 1 |
| van Lingen, RA | 1 |
| van Weissenbruch, MM | 1 |
| Benninga, MA | 1 |
| de Boer, NKH | 1 |
| de Meij, TGJ | 1 |
| Mitra, S | 2 |
| Scrivens, A | 1 |
| von Kursell, AM | 1 |
| Disher, T | 1 |
| Florez, ID | 1 |
| Tamayo, ME | 1 |
| Mbuagbaw, L | 1 |
| Vanniyasingam, T | 1 |
| Veroniki, AA | 1 |
| Zea, AM | 1 |
| Zhang, Y | 1 |
| Sadeghirad, B | 1 |
| Thabane, L | 1 |
| Dijk, P | 1 |
| van Kaam, AHLC | 1 |
| de Tollenaer, SM | 1 |
| Cools, F | 1 |
| van Laere, D | 1 |
| Johansson, AB | 1 |
| Adang, E | 1 |
| de Vries, W | 1 |
| van Heijst, AFJ | 1 |
| Walia, R | 2 |
| Lago, P | 1 |
| Salvadori, S | 1 |
| Opocher, F | 1 |
| Ricato, S | 1 |
| Chiandetti, L | 1 |
| Frigo, AC | 1 |
| Haw, MP | 1 |
| Prescott, S | 1 |
| Keim-Malpass, J | 1 |
| Yoo, H | 1 |
| Lee, JA | 1 |
| Oh, S | 1 |
| Jung, YH | 1 |
| Sohn, JA | 1 |
| Shin, SH | 1 |
| Choi, CW | 1 |
| Kim, EK | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Lee, CH | 1 |
| Chen, HN | 1 |
| Tsao, LY | 1 |
| Hsiao, CC | 1 |
| Lee, ML | 1 |
| Sivanandan, S | 1 |
| Bali, V | 1 |
| Soraisham, AS | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Fakhraee, SH | 1 |
| Badiee, Z | 1 |
| Mojtahedzadeh, S | 1 |
| Kazemian, M | 1 |
| Kelishadi, R | 1 |
| Adamska, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)[NCT01630278] | Phase 3 | 363 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for ibuprofen and Necrotizing Enterocolitis
| Article | Year |
|---|---|
An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants.
Topics: Administration, Oral; Adrenal Cortex Hormones; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2020 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duc | 2020 |
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebral Intraventricular Hemorrhage; Chron | 2020 |
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Bayes Theorem; Cerebral Hemorrhage | 2018 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Enterocolit | 2019 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; | 2013 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizi | 2015 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options.
Topics: Biomarkers; Cardiac Catheterization; Conservative Treatment; Cyclooxygenase Inhibitors; Ductus Arter | 2017 |
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductu | 2000 |
4 trials available for ibuprofen and Necrotizing Enterocolitis
| Article | Year |
|---|---|
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).
Topics: Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotiz | 2018 |
Continuous infusion of ibuprofen for treatment of patent ductus arteriosus in very low birth weight infants.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; Female | 2014 |
Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indo | 2007 |
7 other studies available for ibuprofen and Necrotizing Enterocolitis
| Article | Year |
|---|---|
Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience.
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indomethacin; Infant, Extr | 2023 |
[Clinical features and outcomes of neonatal necrotizing enterocolitis].
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Infant, Newborn; Infant, P | 2019 |
Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Canada; Cardiovascular Surgical Procedures; Cerebral | 2020 |
Predictive factors for surgical treatment in preterm neonates with necrotizing enterocolitis: a multicenter case-control study.
Topics: Case-Control Studies; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Ibuprof | 2021 |
Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Echocardiography; Entero | 2017 |
Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants.
Topics: Administration, Intravenous; Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necroti | 2012 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |